Impact of Conventional Treatments and Clinical Variables on Thyroid Cancer

Thyroid Cancer Clinical Trial

— THY-CANC  

Official title:

Retrospective and Prospective Evaluation of the Impact of Innovative and Conventional Treatments and of Clinical Variables on the Outcome of Thyroid Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05752604
• Other study ID #: 05C212
• Status: Recruiting
• Start date: July 12, 2022
• Est. completion date: March 8, 2042

Study information

• Verified date: April 2024
• Source: Istituto Auxologico Italiano
• Contact: Laura Fugazzola, MD
• Phone: +390261911
• Email: l.fugazzola[@]auxologico.it
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

DTC has a generally favorable prognosis. The possibility to discriminate between patients with aggressive tumors and those with a more indolent behavior may reduce the need for unnecessary treatments. Aim of this observational study is to evaluate how anamnestic, clinical, and histopathological variables may influence the outcome of the enrolled patients, both regarding morbidity and mortality and in terms of therapeutic choices. The study aims to evaluate the prognostic impact of the therapeutic interventions in terms of efficacy and regarding the appearance of adverse events.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 3000
• Est. completion date: March 8, 2042
• Est. primary completion date: March 8, 2032
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• thyroid cancer diagnosis

Exclusion Criteria:

• patients unable to sign informed consent

Related Conditions & MeSH terms

• Thyroid Cancer
• Thyroid Diseases
• Thyroid Neoplasms

Locations

Country	Name	City	State
Italy	Istituto Auxologico Italiano, IRCCS	Milan

Sponsors (1)

Lead Sponsor	Collaborator
Istituto Auxologico Italiano

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dynamic risk stratification	impact of the different variables on the DRS	one year from the primary treatment
Primary	Dynamic risk stratification	impact of the different variables on the DRS	five years from the primary treatment
Primary	Dynamic risk stratification	impact of the different variables on the DRS	ten years from the primary treatment
Primary	Progression-free survival	impact of the different variables on the PFS in patients treated with TKI for advanced thyroid cancer	one year from the primary treatment
Primary	Progression-free survival	impact of the different variables on the PFS in patients treated with TKI for advanced thyroid cancer	five years from the primary treatment
Primary	Progression-free survival	impact of the different variables on the PFS in patients treated with TKI for advanced thyroid cancer	ten years from the primary treatment
Primary	Overall survival	impact of the different variables on the OS in patients treated with TKI for advanced thyroid cancer	one year from the primary treatment
Primary	Overall survival	impact of the different variables on the OS in patients treated with TKI for advanced thyroid cancer	five years from the primary treatment
Primary	Overall survival	impact of the different variables on the OS in patients treated with TKI for advanced thyroid cancer	ten years from the primary treatment